Intellipharmaceutics International Inc. Stock price

Equities

IPCI

CA4581733090

Pharmaceuticals

Delayed Toronto S.E. 12:00:00 2024-03-21 pm EDT 5-day change 1st Jan Change
0.08 CAD 0.00% Intraday chart for Intellipharmaceutics International Inc. 0.00% +6.67%
Sales 2021 - Sales 2022 65.73K 88.99K Capitalization 2.47M 3.34M
Net income 2021 -5M -6.77M Net income 2022 -2M -2.71M EV / Sales 2021 -
Net Debt 2021 1.15M 1.55M Net Debt 2022 2.24M 3.04M EV / Sales 2022 71.6 x
P/E ratio 2021
-0.65 x
P/E ratio 2022
-0.85 x
Employees 11
Yield 2021 *
-
Yield 2022
-
Free-Float 98.24%
More Fundamentals * Assessed data
Dynamic Chart
Current month+23.08%
1 month+23.08%
6 months-20.00%
Current year+6.67%
More quotes
1 month
0.07
Extreme 0.07
0.10
Current year
0.06
Extreme 0.06
0.10
1 year
0.04
Extreme 0.04
0.14
3 years
0.04
Extreme 0.04
0.39
5 years
0.04
Extreme 0.04
1.26
10 years
0.04
Extreme 0.04
51.50
More quotes
Managers TitleAgeSince
Founder - 97-12-31
Chief Executive Officer - 97-12-31
Comptroller/Controller/Auditor - 07-03-31
Members of the board TitleAgeSince
Director/Board Member 68 19-01-21
Chief Executive Officer - 97-12-31
Founder - 97-12-31
More insiders
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. Its product portfolio includes Oxycodone Hydrochloride ER, Regabatin, Dexmethylphenidate ER, Metformin ER, Venlafaxine ER, Pantoprazole ER, Quetiapine ER, Lamotrigine ER, Levetiracetam ER, Desvenlafaxine ER, Ranolazine ER, and Carvedilol ER. Its product portfolio includes both new products and controlled-release generic products. It also provides analytical services.
More about the company
  1. Stock
  2. Equities
  3. Stock Intellipharmaceutics International Inc. - Toronto S.E.